TNF and graft versus host disease: Administration of infliximab, a chimeric IgG1 monoclonal antibody which binds to soluble and transmembrane human TNF-α, has been given to patients for GVHD treatment with some success (36), but there is limited clinical data on the efficacy of infliximab for GVHD prophylaxis, particularly in the GI tract.